Source: Medical Oncology. Unidade: FM
Subjects: NEOPLASIAS HEPÁTICAS (TERAPIA), TAXA DE SOBREVIVÊNCIA, PROGNÓSTICO, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FONSECA, Leonardo Gomes da et al. Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Medical Oncology, v. 31, p. 1-6, 2014Tradução . . Disponível em: https://doi.org/10.1007/s12032-014-0264-5. Acesso em: 10 nov. 2024.APA
Fonseca, L. G. da, Barroso-Sousa, R., Bento, A. da S. A., Blanco, B. P., Valente, G. L., Pfiffer, T. E. F., et al. (2014). Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Medical Oncology, 31, 1-6. doi:10.1007/s12032-014-0264-5NLM
Fonseca LG da, Barroso-Sousa R, Bento A da SA, Blanco BP, Valente GL, Pfiffer TEF, Hoff PM, Sabbaga J. Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib [Internet]. Medical Oncology. 2014 ; 31 1-6.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1007/s12032-014-0264-5Vancouver
Fonseca LG da, Barroso-Sousa R, Bento A da SA, Blanco BP, Valente GL, Pfiffer TEF, Hoff PM, Sabbaga J. Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib [Internet]. Medical Oncology. 2014 ; 31 1-6.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1007/s12032-014-0264-5
